Dermavant to Present Data from Multiple Studies of VTAMA® (tapinarof) cream, 1% at the 2023 Winter Clinical Dermatology Conference
The company anticipates announcing topline results from its pivotal Phase 3 clinical trial program in atopic dermatitis, ADORING 1 and ADORING 2, in the first half of this year.
- The company anticipates announcing topline results from its pivotal Phase 3 clinical trial program in atopic dermatitis, ADORING 1 and ADORING 2, in the first half of this year.
- The following posters will be on display in the Grande Ballroom at the Fairmont Orchid Hotel, as well as digitally throughout the conference.
- The specific mechanisms by which VTAMA cream exerts is therapeutic action in psoriasis and atopic dermatitis are unknown.
- Visit fda.gov/medwatch or call 1-800-FDA-1088 or report side effects to Dermavant Sciences at 1-8 DERMAVANT (1-833-762-8268).